Development of targeting nanotherapeutics against bladder cancer
膀胱癌靶向纳米疗法的开发
基本信息
- 批准号:8442030
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-10-01 至 2017-09-30
- 项目状态:已结题
- 来源:
- 关键词:BindingBiocompatibleBladderBlood CellsCalmette-Guerin BacillusCancer ControlCancer cell lineCanis familiarisCellsChronic CystitisClinicalCompanionsDataDetectionDevelopmentDoctor of MedicineDoctor of PhilosophyDrug Delivery SystemsDrug FormulationsDrug KineticsFibroblastsFundingGoalsHomingHumanImageImmunocompromised HostK-Series Research Career ProgramsKnowledgeLigandsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of urinary bladderMentorsMonitorMusNamesOrganPaclitaxelPatientsPeptidesPharmaceutical PreparationsPharmacology and ToxicologyPilot ProjectsSiteSpecimenStructureSurfaceSystemTherapeuticTherapeutic EffectTimeToxic effectTreatment EfficacyTreatment outcomeUrothelial CellVascular Endothelial CellWorkXenograft procedurecancer celldensitydrug distributiondrug efficacyimprovedin vivointravenous injectionnanotherapeuticnoveloutcome forecastpeptide analogpreclinical studypublic health relevancetargeted deliverytumor xenograft
项目摘要
DESCRIPTION (provided by applicant):
The goal of this project is to develop a nanomicelle drug delivery system that can specifically target bladder cancer. With the funding of the VA Career Development Award-2 (CDA-2, PI: Pan), a bladder cancer-targeting ligand named PLZ4 was developed. PLZ4 binds to both human and dog bladder cancer cell lines and cancer cells from clinical specimens, suggesting that the pre-clinical studies can be performed in dogs with spontaneous bladder cancer. PLZ4 does not bind to normal urothelial cells, inflamed bladder cells, blood cells, vascular endothelial cells an fibroblasts. Recently, Kit Lam, MD, PhD, (Dr. Pan's VA CDA-2 mentor) developed biocompatible and biodegradable nanomicelles. Chemotherapeutic and imaging agents can be loaded inside the nanomicelles. When they are decorated with PLZ4 on surface, these targeting nanomicelles together with the drug load are delivered into bladder cancer cells. Targeting PLZ4-nanomicelles preferentially concentrate at the bladder cancer xenograft sites in vivo and can significantly prolong survival when compared to non-targeting nanomicelles. In this project, we will optimize the structure of the PLZ4-nanomicelles to achieve the maximal drug loading and delivery, and determine the in vivo targeting and drug distribution in mice carrying bladder cancer xenografts developed from human clinical specimens. A pilot study will be conducted in dog patients carrying spontaneous bladder cancer in order to obtain the preliminary toxicity and efficacy data.
PUBLIC HEALTH RELEVANCE:
This project aims to develop a multi-functional nanomicelle drug delivery system that can specifically deliver the chemotherapeutic drug paclitaxel to bladder cancer. The nanomicelle system can possibly improve treatment efficacy and lower therapy-associated toxicity.
描述(由申请人提供):
该项目的目标是开发一种可以特异性靶向膀胱癌的纳米胶束药物递送系统。在 VA 职业发展奖-2(CDA-2,PI:Pan)的资助下,开发了一种名为 PLZ4 的膀胱癌靶向配体。 PLZ4 与人类和狗膀胱癌细胞系以及临床样本中的癌细胞结合,表明临床前研究可以在患有自发性膀胱癌的狗中进行。 PLZ4 不与正常尿路上皮细胞、发炎的膀胱细胞、血细胞、血管内皮细胞和成纤维细胞结合。最近,Kit Lam 博士(潘博士的 VA CDA-2 导师)开发了生物相容性和可生物降解的纳米胶束。 化疗剂和显像剂可以装载在纳米胶束内。当它们的表面用 PLZ4 装饰时,这些靶向纳米胶束与药物负载一起被递送到膀胱癌细胞中。靶向 PLZ4 纳米胶束优先集中在体内膀胱癌异种移植部位,与非靶向纳米胶束相比,可以显着延长生存期。在这个项目中,我们将优化PLZ4纳米胶束的结构,以实现最大的药物装载和递送,并确定携带从人类临床标本开发的膀胱癌异种移植小鼠的体内靶向和药物分布。一项试点研究将在患有自发性膀胱癌的狗患者中进行,以获得初步的毒性和疗效数据。
公共卫生相关性:
该项目旨在开发一种多功能纳米胶束药物递送系统,能够特异性地将化疗药物紫杉醇递送至膀胱癌。纳米胶束系统可能会提高治疗效果并降低治疗相关的毒性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHONG-XIAN PAN其他文献
CHONG-XIAN PAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHONG-XIAN PAN', 18)}}的其他基金
BCCMA: Translational research to improve the care of advanced bladder cancer
BCCMA:改善晚期膀胱癌护理的转化研究
- 批准号:
10588312 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
癌症靶向胶束治疗非肌浸润性膀胱癌的 I 期试验
- 批准号:
10426035 - 财政年份:2020
- 资助金额:
-- - 项目类别:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
癌症靶向胶束治疗非肌浸润性膀胱癌的 I 期试验
- 批准号:
10578717 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
- 批准号:
10158416 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
- 批准号:
9898243 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
- 批准号:
10085104 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Targeted-and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向定时释放纳米疗法
- 批准号:
10162055 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向和定时释放纳米疗法
- 批准号:
9260776 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向和定时释放纳米疗法
- 批准号:
9454297 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Development of targeting nanotherapeutics against bladder cancer
膀胱癌靶向纳米疗法的开发
- 批准号:
9275369 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
SpyTCR-RBNP - Engineering a highly targeted and biocompatible drug delivery system for solid cancer treatment
SpyTCR-RBNP - 设计用于实体癌症治疗的高度针对性和生物相容性的药物输送系统
- 批准号:
10095606 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Collaborative R&D
Biocompatible Pickering Nanoemulsions for Cosmetics Applications
用于化妆品应用的生物相容性 Pickering 纳米乳液
- 批准号:
2902166 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship
Biology the initiator: Harnessing Reactive Oxygen Species for Biocompatible Polymerization
生物学引发者:利用活性氧进行生物相容性聚合
- 批准号:
10667740 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Theoretical development of biocompatible and shape-memorable magnesium alloys
生物相容性形状记忆镁合金的理论发展
- 批准号:
22KF0239 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
ERI: Durability of Biocompatible Elastomers under Extreme Environments: Unveiling the Aging Mechanisms
ERI:极端环境下生物相容性弹性体的耐久性:揭示老化机制
- 批准号:
2301031 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
FET: Small: Hybrid Electrical, Ionic, and Biocompatible Artificial Synaptic Transistors
FET:小型:混合电气、离子和生物相容性人工突触晶体管
- 批准号:
2246855 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Biocompatible Flexible Microfabricated Sensors for Surgical Applications
适用于外科应用的生物相容性柔性微加工传感器
- 批准号:
2321238 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Metal extraction using biocompatible ionic liquid system assisted by machine learning
机器学习辅助下使用生物相容性离子液体系统提取金属
- 批准号:
22KF0286 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
Biocompatible fluorophores for shortwave infrared imaging
用于短波红外成像的生物相容性荧光团
- 批准号:
10737471 - 财政年份:2023
- 资助金额:
-- - 项目类别:
BIOSCIENCE FOR RENEWABLE RESOURCES AND CLEAN GROWTH - Expanding Synthetic Biology using Biocompatible Reactions
可再生资源和清洁增长的生物科学 - 利用生物相容性反应扩展合成生物学
- 批准号:
2890724 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship